BR112023026258A2 - Terapia genética para esclerose tuberosa - Google Patents

Terapia genética para esclerose tuberosa

Info

Publication number
BR112023026258A2
BR112023026258A2 BR112023026258A BR112023026258A BR112023026258A2 BR 112023026258 A2 BR112023026258 A2 BR 112023026258A2 BR 112023026258 A BR112023026258 A BR 112023026258A BR 112023026258 A BR112023026258 A BR 112023026258A BR 112023026258 A2 BR112023026258 A2 BR 112023026258A2
Authority
BR
Brazil
Prior art keywords
gene therapy
tuberous sclerosis
methods
compositions
aav
Prior art date
Application number
BR112023026258A
Other languages
English (en)
Portuguese (pt)
Inventor
Wayne Scott David
Original Assignee
Bridgebio Gene Therapy Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bridgebio Gene Therapy Res Inc filed Critical Bridgebio Gene Therapy Res Inc
Publication of BR112023026258A2 publication Critical patent/BR112023026258A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C07K14/4706—Guanosine triphosphatase activating protein, GAP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BR112023026258A 2021-06-14 2022-06-14 Terapia genética para esclerose tuberosa BR112023026258A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163210456P 2021-06-14 2021-06-14
PCT/US2022/033452 WO2022266113A1 (en) 2021-06-14 2022-06-14 Gene therapy for tuberous sclerosis

Publications (1)

Publication Number Publication Date
BR112023026258A2 true BR112023026258A2 (pt) 2024-02-27

Family

ID=83080777

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023026258A BR112023026258A2 (pt) 2021-06-14 2022-06-14 Terapia genética para esclerose tuberosa

Country Status (7)

Country Link
US (1) US20240261439A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355766A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024522943A (cg-RX-API-DMAC7.html)
CN (1) CN117715928A (cg-RX-API-DMAC7.html)
BR (1) BR112023026258A2 (cg-RX-API-DMAC7.html)
CA (1) CA3223219A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022266113A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116875636A (zh) * 2023-07-05 2023-10-13 四川大学华西医院 胶原靶向的干细胞源外泌体的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
WO2004058166A2 (en) 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US7561972B1 (en) 2008-06-06 2009-07-14 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
US7561973B1 (en) 2008-07-31 2009-07-14 Dna Twopointo, Inc. Methods for determining properties that affect an expression property value of polynucleotides in an expression system
US11958887B2 (en) 2017-05-17 2024-04-16 The General Hospital Corporation Gene therapy for tuberous sclerosis

Also Published As

Publication number Publication date
JP2024522943A (ja) 2024-06-21
CA3223219A1 (en) 2022-12-22
WO2022266113A1 (en) 2022-12-22
CN117715928A (zh) 2024-03-15
US20240261439A1 (en) 2024-08-08
EP4355766A1 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
BR112021020957A2 (pt) Capsídeos de vírus adenoassociado (aav) variante para liberação intravítrea
MX2021013420A (es) Composiciones utiles en el tratamiento de leucodistrofia metacromatica.
BR112022000724A2 (pt) Proteínas de capsídeo de aav modificado para tratamento de doença artrítica
BR112022022644A2 (pt) Composições de vírus adeno-associados compatíveis com espécies cruzadas e método de uso destas
BR112018011975A2 (pt) composições úteis no tratamento de atrofia muscular espinhal
CL2022000939A1 (es) Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c
JOP20220043A1 (ar) بروتين كابسيد vp1 معدل معزول من aav5
BR112022004027A2 (pt) Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte
WO2020219766A8 (en) Compositions useful in treatment of rett syndrome
EA202091194A1 (ru) Вирусные векторы, содержащие области, кодирующие rdh12, и способы лечения дистрофий сетчатки
BR112021023473A2 (pt) Vetores de terapia genética para osteopetrose maligna infantil
BR112022023908A2 (pt) Composições de vírus adenoassociados para restauração da função do gene pah e métodos de uso das mesmas
WO2023004407A3 (en) Adeno-associated virus compositions and methods of use thereof
BR112022021762A2 (pt) Composições úteis em tratamento de distúrbio de deficiência de cdkl5 (cdd)
BR112021020706A2 (pt) Métodos e composições para expressão de transgene
CO2024013743A2 (es) Terapia génica dirigida para la distrofia miotónica dm-1
BR112022003206A2 (pt) Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte
UY39426A (es) Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela) con aav-mir-sod1
CO2025015074A2 (es) Terapia génica dirigida para la distrofia miotónica dm-1
BR112022026997A2 (pt) Vetor de vírus adeno-associado para quadro de leitura aberto dwarf
JOP20240034A1 (ar) بروتين كابسيد vp1 معدل مفصول يخص الفيروس aav9
BR112022019182A2 (pt) Composições de vírus adeno-associadas para transferência do gene ids e métodos de uso da mesma
AR134214A1 (es) Redireccionamiento de cápsides de aav para dirigirlas al sistema nervioso central
WO2024064782A3 (en) Adeno-associated virus capsids
GEAP202516788A (en) Pharmaceutical composition of non-enveloped virus